Table 2.

Table 2A. Antibody-Mediated Rejection Incidence and Presentationa, by Transplant Type
Transplant Type	Incidence of AMR
	Overall (n=219)	Subclinical Presentationb (n=77)	Clinical Presentation (n=142)
Deceased Donor: Compatible	1.7%	0.1%	1.6%
Deceased Donor: HLA-Incompatible	44.7%	16.5%	28.2%
Live Donor: Compatible	0.7%	0.5%	0.2%
Live donor: ABO-Incompatiblec	13.6%	2.5%	11.1%
Live Donor: HLA-Incompatible	47.4%	18.1%	29.3%
Overall	9.5%	3.3%	6.1%

Table 2B. Antibody-Mediated Rejection Risk of Graft Loss, by Transplant Type
Transplant Type	Hazard Ratiod	P-value
Deceased Donor: Compatible	4.73 (1.57–14.26)	0.006
Deceased Donor: HLA-Incompatible	2.39 (1.10–5.19)	0.028
Live Donor: Compatible	NAe	--
Live donor: ABO-Incompatiblec	6.13 (0.55–67.70)	0.1
Live Donor: HLA-Incompatible	6.29 (3.81–10.39)	0.001
Overall	4.61 (3.19–6.68)	<0.001

AMR=antibody-mediated rejection

^a- Clinical AMR was distinguished from subclinical AMR by the presence of evidence of graft dysfunction, manifested as oliguria/anuria, an increase in serum creatinine by ≥20% from baseline, treatment of cell-mediated rejection and/or thrombotic microangiopathy within the two prior weeks, the need for hemodialysis>7 days post-transplant, or new onset proteinuria at the time of the AMR-defining biopsy.

^b- The test for trend of differences in incidence of AMR presentation (subclinical vs. clinical) across transplant types was statistically significant (P=0.027).

^c- Patients who were ABO-incompatible with their donor and also had anti-HLA donor-specific antibody were studied as members of the HLA-incompatible live donor group (n=43; 14.7% of the HLA-incompatible live donor recipient population.

^d- Refers to hazard ratio comparing AMR patients of a transplant type with patients of the same transplant type who did not develop AMR.

^e- Hazard ratio could not be calculated as no compatible live donor recipients with AMR had a graft loss during the study period.